» Articles » PMID: 14603456

Salvage of Recurrent Head and Neck Squamous Cell Carcinoma After Primary Curative Surgery

Overview
Journal Head Neck
Date 2003 Nov 7
PMID 14603456
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The efficacy of salvage treatment of recurrent head and neck squamous cell carcinomas (HNSCC) after primary curative surgery was evaluated.

Methods: The management outcome of 377 patients who had recurrent squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, and larynx after primary curative surgery was reviewed.

Results: The surgical salvage rates of recurrence were 29% local, 30% tracheostomal, 56% unilateral nodal recurrence of previously undissected neck, 32% of unilateral neck recurrence after prior neck dissection, and 11% lung metastasis. The 5-year tumor-free actuarial survival rates of those patients who received surgical salvage was 35% for local recurrence, 32% for unilateral nodal recurrence of the previously undissected neck, and 18% for nodal recurrence of the previously dissected neck. One patient of six with tracheostomal recurrence salvaged with surgery and one patient of six with lung metastasis salvaged with lobectomy survived without tumor at 5 years. There was no 5-year survivor of all patients salvaged with other nonsurgical methods. The mean survival of patients without surgical salvage was 6 months.

Conclusions: There was a moderate chance of cure after surgical salvage of locoregional recurrent HNSCC. Surgical salvage was, however, only feasible for early recurrent tumor. Close follow-up surveillance of early recurrence is essential after primary treatment of patients.

Citing Articles

3-year overall survival benefit of systematic follow-up with 18F-FDG PET/CT in asymptomatic patients treated for head and neck squamous cell carcinoma: a multicenter study.

Maheo C, Abgral R, Clement C, Malard O, Espitalier F, Ferron C Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40000460 DOI: 10.1007/s00259-025-07147-9.


Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy.

Belfiore M, Nardone V, DOnofrio I, Pirozzi M, Sandomenico F, Farese S Biomedicines. 2024; 12(9).

PMID: 39335592 PMC: 11428618. DOI: 10.3390/biomedicines12092080.


Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck.

Sato M, Enokida T, Fujisawa T, Okano S, Takeshita N, Tanaka N Front Oncol. 2024; 14:1420860.

PMID: 39011480 PMC: 11246904. DOI: 10.3389/fonc.2024.1420860.


The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?.

Rayan A, Shahine M, Rezk K, Zahran A, Aboshanif M, Gamal D Ecancermedicalscience. 2024; 17:1611.

PMID: 38414964 PMC: 10898904. DOI: 10.3332/ecancer.2023.1611.


Regional Nodal Recurence as a Prognostic Factor in Patients Kept on Observation for cT1-T2 Oral Squamous Cell Carcinomas of Tongue: A Meta-Analysis of 11,973 Patients.

Akheel M, Wadhwania A, Venkataramu V, Vijay T, Qazi M, Suneja R Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3750-3756.

PMID: 37974831 PMC: 10645994. DOI: 10.1007/s12070-023-04057-w.